A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

Also called NCT05255458

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 122 participants (enrolled count) (from the registry)
Sponsor
  • Akeso Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05255458
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05255458. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-04 (actual); primary completion 2023-01-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
Condition
Hyperlipidemia
Intervention (Biological)
AK102
Intervention (Drug)
Placebo
Lead sponsor
Akeso (class: industry)

Record details

Record id
cardio:ct-nct05255458
Content hash
756b85a792fc531e14a7175722c6cef0bf217f5d34131caa7ffd772491a92bf9